Technology Guidance

Recombinant blood products

for prophylaxis and management of haemophilia A and B

Recommendations from the MOH Drug Advisory Committee

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended the following recombinant blood products for inclusion on the MOH Standard Drug List (SDL) for patients with haemophilia A (congenital factor VIII deficiency) and haemophilia B (congenital factor IX deficiency) in line with their registered indications when used as treatment and prophylaxis of bleeding episodes:

- ✓ Octocog alfa (Advate) 250 IU, 500 IU, 1000 IU and 1500 IU powder and solvent for solution for injection
- ✓ Rurioctocog alfa pegol (Adynovate) 250 IU, 500 IU, 1000 IU, 1500 IU, 2000 IU and 3000 IU powder and solvent for solution for injection
- ✓ Nonacog alfa (BeneFIX) 250 IU, 500 IU, 1000 IU and 2000 IU powder and solvent for solution for injection

Blood products that have not been recommended for subsidy due to unacceptable cost-effectiveness compared with subsidised alternatives are listed in the Annex.

The subsidy class and subsidy implementation dates (if applicable) for all blood products included in the review are provided in the Annex.

Published: 19 December 2022

ANNEX

Recommendations by the MOH Drug Advisory Committee

Product class	Product (Brand)	Subsidy class (implementation date)
Haemophilia A		
Standard half-life recombinant factor VIII	Octocog alfa (Advate) 250 IU, 500 IU, 1000 IU and 1500 IU powder and solvent for solution for injection	SDL (1 Feb 2023)
	Moroctocog alfa (Xyntha) 250 IU, 500 IU, 1000 IU and 2000 IU powder and solvent for solution for injection	SDL^
	Simoctocog alfa (Nuwiq) 250 IU, 500 IU, 1000 IU and 2000 IU powder and solvent for solution for injection	Not recommended for subsidy
	Turoctocog alfa (Novoeight) 250 IU, 500 IU and 1000 IU powder and solvent for solution for injection	Not recommended for subsidy
Extended half-life recombinant factor VIII	Rurioctocog alfa pegol (Adynovate) 250 IU, 500 IU, 1000 IU, 1500 IU, 2000 IU and 3000 IU powder and solvent for solution for injection	SDL (1 Feb 2023)
	Lonoctocog alfa (Afstyla) 250 IU, 500 IU, 1000 IU, 2000 IU and 3000 IU powder and solvent for solution for injection	Not recommended for subsidy
Haemophilia B		
Standard half-life recombinant factor IX	Nonacog alfa (BeneFIX) 250 IU, 500 IU, 1000 IU and 2000 IU powder and solvent for solution for injection	SDL (1 Feb 2023)
Extended half-life recombinant factor IX	Albutrepenonacog alfa (Idelvion) 250 IU, 500 IU, 1000 IU and 2000 IU powder and solvent for solution for injection	Not recommended for subsidy

Abbreviations: SDL, Standard Drug List
^ No change in listing

About the Agency

The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidance, and education.

As the national HTA agency, ACE conducts evaluations to inform government subsidy decisions for treatments, diagnostic tests and vaccines, and produces guidance for public hospitals and institutions in Singapore.

This guidance is based on the evidence available to the MOH Drug Advisory Committee as at 18 March 2022, 24 June 2022, 25 August 2022, 15 September 2022. It is not, and should not be regarded as, a substitute for professional or medical advice. Please seek the advice of a qualified healthcare professional about any medical condition. The responsibility for making decisions appropriate to the circumstances of the individual patient remains with the healthcare professional.

Find out more about ACE at www.ace-hta.gov.sg/about

Chief HTA Officer
Agency for Care Effectiveness
Email: ACE_HTA@moh.gov.sg